← Back to Screener
Inovio Pharmaceuticals, Inc. (INO)
Price$1.16
Favorite Metrics
Price vs S&P 500 (26W)-57.50%
Price vs S&P 500 (4W)-34.14%
Market Capitalization$98.19M
All Metrics
Book Value / Share (Quarterly)$0.35
P/TBV (Annual)1.19x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-81.47%
Cash Flow / Share (Quarterly)$-1.29
Price vs S&P 500 (YTD)-34.25%
Gross Margin (TTM)58.85%
Net Profit Margin (TTM)-25107.34%
EPS (TTM)$-1.93
10-Day Avg Trading Volume4.75M
EPS Excl Extra (TTM)$-1.93
Revenue Growth (5Y)-61.18%
EPS (Annual)$-1.81
ROI (Annual)-352.53%
Gross Margin (Annual)60.13%
Net Profit Margin (5Y Avg)-43066.73%
Cash / Share (Quarterly)$0.85
ROA (Last FY)-114.31%
Revenue Growth TTM (YoY)-69.99%
EBITD / Share (TTM)$-1.84
ROE (5Y Avg)-165.21%
Operating Margin (TTM)-27701.47%
Cash Flow / Share (Annual)$-1.29
P/B Ratio4.07x
P/B Ratio (Quarterly)4.96x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)190.44x
Net Interest Coverage (TTM)-43.65x
ROA (TTM)-113.56%
EPS Incl Extra (Annual)$-1.81
Current Ratio (Annual)1.40x
Quick Ratio (Quarterly)1.34x
3-Month Avg Trading Volume1.66M
52-Week Price Return-32.77%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.15
P/S Ratio (Annual)1502.70x
Asset Turnover (Annual)0.00x
52-Week High$2.98
Operating Margin (5Y Avg)-44274.27%
EPS Excl Extra (Annual)$-1.81
CapEx CAGR (5Y)-28.42%
Tangible BV CAGR (5Y)-2.96%
26-Week Price Return-53.52%
Quick Ratio (Annual)1.34x
13-Week Price Return-22.73%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.40x
Enterprise Value$53.913
Revenue / Share Growth (5Y)-69.97%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-58.86%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.19x
Pretax Margin (Annual)-130005.97%
Cash / Share (Annual)$0.85
3-Month Return Std Dev85.10%
Gross Margin (5Y Avg)63.72%
Net Income / Employee (TTM)$-1
ROE (Last FY)-352.53%
Net Interest Coverage (Annual)-1.04x
EPS Basic Excl Extra (Annual)$-1.81
P/FCF (TTM)6.71x
Receivables Turnover (TTM)0.11x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.93
Receivables Turnover (Annual)0.11x
ROI (TTM)-113.93%
P/S Ratio (TTM)346.84x
Pretax Margin (5Y Avg)-43057.61%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.15
Price vs S&P 500 (52W)-62.60%
Year-to-Date Return-31.61%
5-Day Price Return13.33%
EPS Normalized (Annual)$-1.81
ROA (5Y Avg)-85.92%
Net Profit Margin (Annual)-130005.97%
Month-to-Date Return-31.61%
Cash Flow / Share (TTM)$-0.62
EBITD / Share (Annual)$-1.88
Operating Margin (Annual)-132877.43%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-160.03%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.93
P/TBV (Quarterly)1.19x
P/B Ratio (Annual)4.96x
Inventory Turnover (TTM)2.11x
Pretax Margin (TTM)-25107.34%
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)-23.41%
Beta1.62x
Revenue / Share (TTM)$0.00
ROE (TTM)-113.93%
52-Week Low$1.03
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INOInovio Pharmaceuticals, Inc. | 346.84x | -69.99% | 58.85% | — | $1.16 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Inovio Pharmaceuticals is a biotechnology company developing DNA-based immunotherapies for HPV-associated diseases, cancer, and infectious diseases. The company's proprietary electroporation technology enables targeted delivery and enhanced immunogenicity of its DNA medicine candidates.